Advanced Filters
noise

Peking, China Clinical Trials

A listing of Peking, China clinical trials actively recruiting patients volunteers.

Found 2,907 clinical trials
W Wenyu Guo, MD,PhD

Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension

In this multicenter, randomized, placebo-controlled trial in pre-heat failure patients with hypertension and without diabetes, we will enroll 120 eligible patients to randomized to receive placebo or engagliflozin (10mg/d) for follow them for 6 months. The primary endpoint is the left atrial volume index, which reflects left ventricular diastolic function. …

18 years of age All Phase 4
R Rui Wang, MD

Evaluation of Membrane Lung Function in High-altitude Regions

Over the last 20 years, extracorporeal membrane oxygenation (ECMO) has been used to support adult patients with respiratory or cardiac failure who are unlikely to survive conventional treatment methods. ECMO circuit, pump, and oxygenator technology improvements permit safer perfusion for extended periods. The prolonged use of an ECMO circuit increases …

18 - 70 years of age All Phase N/A
H Hongyan Tong, Doctor

A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas

Study GLB-002-01 is a first-in-human (FIH), phase 1, open-label, dose escalation and expansion clinical study, the purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of GLB-002 monotherapy in participants with relapsed or refractory Non-Hodgkin lymphomas (R/R NHL).

18 years of age All Phase 1
J Jun Huang

A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)

The study is being conducted to compare JS004 plus Toripalimab with Investigator-Selected Chemotherapy in Patients with PD-(L)1 monoclonal antibody refractory Classic Hodgkin Lymphoma (cHL)

18 years of age All Phase 3
B Binghe Xu

A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors

This is a Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of IAP0971 in Patients with Advanced Malignant Tumors.

18 - 75 years of age All Phase 1/2

A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.

The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A1811 combined with other antitumor therapies in advanced solid tumors. To explore the reasonable dosage of SHR-A1811 combined with other antitumor therapies for advanced solid tumors.

18 - 75 years of age All Phase 1/2

A Clinical Study of T3011 in Subjects With Advanced Melanoma

This clinical study evaluated the tolerability, safety and preliminary efficacy of T3011 in subjects with advanced melanoma.

18 years of age All Phase 1/2

Clinical Study of Individualized Treatment of Relapsed or Drug-resistant Advanced Gynecological Tumors Guided by PTC Model

The clinical treatment of patients with resistant/relapsed/advanced gynecological malignancies is very difficult, and the difficulty lies in the selection of effective drugs. This study was a cohort study of recurrent/drug-resistant advanced ovarian high-grade serous carcinoma and advanced/recurrent endometrial adenocarcinoma treated in our hospital. A total of 20 cases were included …

18 - 80 years of age Female Phase N/A
H Haitao Zhao, MD

Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer

Explore the impact of the first-line application of Pembrolizumab with or without Lenvatinib or chemotherapy, on the survival, disease progression, and drug safety of patients with advanced biliary tract cancers

18 - 80 years of age All Phase 2
S SHEN LIN

A First-in-human of Multiplle Doses of BB-1709 in Subjects With Locally Advanced/Metastatic Solid Tumors

The goal of this clinical trial is to test in patients with local advanced/metastatic solid tumors. the main questions it aims to answer are: to assess the safety and tolerability of BB-1709. to determine the maximum tolerated dose(MTD) and/or the PR2D of BB-1709

18 - 78 years of age All Phase 1

Simplify language using AI